8,898 Shares in Vaxcyte, Inc. $PCVX Bought by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. acquired a new position in Vaxcyte, Inc. (NASDAQ:PCVX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 8,898 shares of the company’s stock, valued at approximately $517,000.

Other institutional investors have also modified their holdings of the company. Royal Bank of Canada lifted its holdings in Vaxcyte by 115.2% in the first quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock worth $1,113,000 after acquiring an additional 15,774 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Vaxcyte in the 1st quarter worth about $219,000. Caxton Associates LLP acquired a new position in shares of Vaxcyte during the first quarter worth approximately $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Vaxcyte by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock worth $19,409,000 after buying an additional 41,034 shares during the period. Finally, Cetera Investment Advisers grew its holdings in Vaxcyte by 13.8% in the 2nd quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock worth $250,000 after buying an additional 932 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Trading Down 3.1%

Shares of Vaxcyte stock opened at $61.34 on Friday. Vaxcyte, Inc. has a 52 week low of $29.87 and a 52 week high of $65.00. The stock has a market cap of $9.13 billion, a PE ratio of -8.04 and a beta of 1.23. The company’s 50-day moving average price is $56.12 and its two-hundred day moving average price is $55.76.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same quarter in the prior year, the business posted ($1.22) EPS. On average, equities analysts predict that Vaxcyte, Inc. will post -7.6 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on PCVX. Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Vaxcyte currently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Insider Buying and Selling at Vaxcyte

In related news, insider Harpreet S. Dhaliwal sold 17,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total transaction of $935,000.00. Following the completion of the sale, the insider directly owned 76,756 shares in the company, valued at approximately $4,221,580. This trade represents a 18.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.89, for a total transaction of $538,900.00. Following the sale, the chief financial officer owned 105,176 shares of the company’s stock, valued at $5,667,934.64. The trade was a 8.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 120,646 shares of company stock valued at $6,570,810 in the last ninety days. Company insiders own 3.30% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.